| 产品描述: | SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer[1] |
| 靶点: |
IC50: 0.69 μM (matriptase); 0.65 μM (hepsin); 0.30 μM (HGFA);c-Met/HGFR |
| 参考文献: |
1. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.874 ml |
9.37 ml |
18.741 ml |
| 5 mM |
0.375 ml |
1.874 ml |
3.748 ml |
| 10 mM |
0.187 ml |
0.937 ml |
1.874 ml |
| 50 mM |
0.037 ml |
0.187 ml |
0.375 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |